BeOne Medicines (BEIGF) Cash & Equivalents Growth (3y) (2018 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Cash & Equivalents Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | -1.21% |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | -9.15% |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | 6.56% |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | -11.22% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | -28.16% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -5.35% |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 8.35% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 19.10% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 14.34% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.34% |
| Mar 31, 2026 | 10.63% |
| Dec 31, 2025 | 5.53% |
| Sep 30, 2025 | -1.29% |
| Jun 30, 2025 | -15.27% |
| Mar 31, 2025 | -16.66% |
| Dec 31, 2024 | -15.64% |
| Sep 30, 2024 | 25.00% |
| Jun 30, 2024 | 13.43% |
| Mar 31, 2024 | 13.67% |
| Dec 31, 2023 | 31.91% |
| Sep 30, 2023 | 27.95% |
| Jun 30, 2023 | 36.36% |
| Mar 31, 2023 | 21.83% |
| Dec 31, 2022 | 84.31% |
| Sep 30, 2022 | 69.83% |
| Jun 30, 2022 | 70.20% |
| Mar 31, 2022 | 78.49% |
| Dec 31, 2021 | 83.09% |
| Sep 30, 2021 | 29.06% |